Harrow Labs produces a drug used for the treatment of arthritis. The drug is produced in batches. In March, Harrow, which had no opening inventory, processed one batch of chemicals. It sold 1, 600 gallons of product for human use and 350 gallons of the veterinarian product. Harrow uses the net realizable value method for allocating joint production costs Chemicals costing $ 55000 are mixed and heated, then a unique separation process then extracts the drug from the mixture. A batch yields a total of 3000 gallons of the chemicals. The first 2400 gallons are sold for human use while the last 600 gallons, which contain impurities, are sold to veterinarians. The costs of mixing, heating, and extracting the drug amount to $ 466400 per batch. The output sold for human use is pasteurized at a total cost of $ 134400 and is sold for $ 580 per gallon. The product sold to veterinarians is irradiated at a cost of $ 19 per gallon and is sold for $ 460 per gallon. REQUIREMENTS; 1. How much in joint costs does Harrow allocate to each product? 2. Compute the cost of ending inventory for each of Harrow's products. 3. If Harrow were to use the constant gross-margin percentage NRV method instead, how would it allocate its joint costs? 4. Calculate the gross margin on the sale of the product for human use in March under the constant gross-margin percentage NRV method. 5. Suppose that the separation process also yields 250 pints of a toxic byproduct. Harrow currently pays a hauling company $ 6300 to dispose of this byproduct. Harrow is contacted by a firm interested in purchasing a modified form of this byproduct for a total price of $ 6800. Harrow estimates that it will cost about $ 42 per pint to do the required modification. Should Harrow accept the offer? Please show the calculations especially for number 1. thanks